Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida. more
Time Frame | ENTO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 8.77% | -0.94% | -2.6% |
1-Month Return | 31.63% | -5.08% | -1.08% |
3-Month Return | 99.36% | -10.62% | 3.45% |
6-Month Return | -65.01% | -6.18% | 8.57% |
1-Year Return | -83.2% | 1.98% | 24.3% |
3-Year Return | -99.99% | -0.93% | 25.58% |
5-Year Return | -100% | 33.84% | 84.07% |
10-Year Return | -100% | 102.52% | 185.12% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 571.14K | 537.40K | 106.21K | 29.27K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.09,"profit":true},{"date":"2022-12-31","value":18.6,"profit":true},{"date":"2023-12-31","value":5.13,"profit":true}] | |
Gross Profit | (571.14K) | (537.40K) | (106.21K) | (29.27K) | [{"date":"2020-12-31","value":-57114500,"profit":false},{"date":"2021-12-31","value":-53740000,"profit":false},{"date":"2022-12-31","value":-10620700,"profit":false},{"date":"2023-12-31","value":-2927400,"profit":false}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 26.43M | 56.70M | 12.68M | 15.77M | [{"date":"2020-12-31","value":46.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.36,"profit":true},{"date":"2023-12-31","value":27.81,"profit":true}] | |
Operating Income | (26.43M) | (59.06M) | (12.68M) | (15.77M) | [{"date":"2020-12-31","value":-2643276800,"profit":false},{"date":"2021-12-31","value":-5905688800,"profit":false},{"date":"2022-12-31","value":-1267806600,"profit":false},{"date":"2023-12-31","value":-1577082700,"profit":false}] | |
Total Non-Operating Income/Expense | (12.08M) | (1.84M) | (1.96M) | (44.09K) | [{"date":"2020-12-31","value":-1207882800,"profit":false},{"date":"2021-12-31","value":-184301100,"profit":false},{"date":"2022-12-31","value":-195904000,"profit":false},{"date":"2023-12-31","value":-4408800,"profit":false}] | |
Pre-Tax Income | (32.67M) | (58.54M) | (14.63M) | (15.79M) | [{"date":"2020-12-31","value":-3267146600,"profit":false},{"date":"2021-12-31","value":-5853784900,"profit":false},{"date":"2022-12-31","value":-1462964200,"profit":false},{"date":"2023-12-31","value":-1579498300,"profit":false}] | |
Income Taxes | 15.11M | 26.52M | 126.56K | 326.37K | [{"date":"2020-12-31","value":56.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.48,"profit":true},{"date":"2023-12-31","value":1.23,"profit":true}] | |
Income After Taxes | (47.78M) | (85.06M) | (14.76M) | (16.12M) | [{"date":"2020-12-31","value":-4778438200,"profit":false},{"date":"2021-12-31","value":-8505892400,"profit":false},{"date":"2022-12-31","value":-1475620700,"profit":false},{"date":"2023-12-31","value":-1612135000,"profit":false}] | |
Income From Continuous Operations | (32.67M) | (58.54M) | (14.63M) | (15.79M) | [{"date":"2020-12-31","value":-3267146600,"profit":false},{"date":"2021-12-31","value":-5853784900,"profit":false},{"date":"2022-12-31","value":-1462964200,"profit":false},{"date":"2023-12-31","value":-1579498300,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (32.67M) | (58.54M) | (14.63M) | (15.79M) | [{"date":"2020-12-31","value":-3267146600,"profit":false},{"date":"2021-12-31","value":-5853784900,"profit":false},{"date":"2022-12-31","value":-1462964200,"profit":false},{"date":"2023-12-31","value":-1579498300,"profit":false}] | |
EPS (Diluted) | (61.36K) | (46.51K) | (3.57K) | (88.81) | [{"date":"2020-12-31","value":-6135944.94,"profit":false},{"date":"2021-12-31","value":-4650605.8,"profit":false},{"date":"2022-12-31","value":-357124.29,"profit":false},{"date":"2023-12-31","value":-8881.36,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
ENTO | |
---|---|
Cash Ratio | 0.02 |
Current Ratio | 5.34 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ENTO | |
---|---|
ROA (LTM) | -27.07% |
ROE (LTM) | -15.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ENTO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ENTO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.07 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Entero Therapeutics, Inc. (ENTO) share price today is $0.62
Yes, Indians can buy shares of Entero Therapeutics, Inc. (ENTO) on Vested. To buy Entero Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENTO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Entero Therapeutics, Inc. (ENTO) via the Vested app. You can start investing in Entero Therapeutics, Inc. (ENTO) with a minimum investment of $1.
You can invest in shares of Entero Therapeutics, Inc. (ENTO) via Vested in three simple steps:
The 52-week high price of Entero Therapeutics, Inc. (ENTO) is $14.51. The 52-week low price of Entero Therapeutics, Inc. (ENTO) is $0.18.
The price-to-earnings (P/E) ratio of Entero Therapeutics, Inc. (ENTO) is
The price-to-book (P/B) ratio of Entero Therapeutics, Inc. (ENTO) is 0.07
The dividend yield of Entero Therapeutics, Inc. (ENTO) is 0.00%
The market capitalization of Entero Therapeutics, Inc. (ENTO) is $1.11M
The stock symbol (or ticker) of Entero Therapeutics, Inc. is ENTO